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ABSTRACT
Background: Early diagnosis of head and neck cancer (HNC) will improve patient outcomes.
The low incidence of HNC renders its detection challenging for a general practitioner (GP) in pri-
mary health care (PHC).
Patients and methods: To examine these challenges, our cohort consisted of all patients visit-
ing PHC centres in the City of Helsinki in 2016. We chose 57 ICD-10 codes representing a sign
or symptom resulting from a possible HNC and compared data for all new HNC patients.
Results: A total of 242,211 patients (499,542 appointments) visited PHC centres, 11,896 (5%) of
whom presented with a sign or symptom possibly caused by HNC. Altogether, 111 new HNCs
were diagnosed within the Helsinki area, of which 40 (36%) were referred from PHC. The median
delay from the initial PHC visit to the referral to specialist care was 5 days, whereby 88% of
patients were referred within one month.
Conclusions: Despite the low incidence of HNC and the large number of patients presenting
with HNC-related symptoms, GPs working in PHC sort out potential HNC patients from the gen-
eral patient group in most cases remarkably effectively.
KEY MESSAGES
 For every head and neck cancer (HNC) patient encountered in the primary health care, a gen-
eral practitioner (GP) will meet approximately 6000 other patients, 100 of whom exhibit a
sign or a symptom potentially caused by a HNC.
 Despite the low incidence of HNC, GPs referred patients to specialist care effectively, limiting
the median delay from the initial appointment to referral to only 5 days.
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Any delay in the diagnosis and treatment of head and
neck cancer (HNC) might affect patient outcome [1–5].
The worldwide incidence of HNC was 11.6/100,000 in
2018 [6]. Given this low incidence, the proportion of HNC
patients compared to the patient population a single GP
encounters while working in a public primary health care
(PHC) center may remain quite small. Furthermore, HNC
might cause a variety of symptoms that commonly
accompany benign conditions as well, such as pain in
the throat. In a recent Swedish study of 114,538 ran-
domly selected adults from the general population, the
prevalence of voice problems (tiring, strain or hoarseness)
was 16.9% [7]. Another population-based study among
randomly selected adults from the United States found
that symptoms indicative of chronic rhinosinusitis were
reported by 11.5% of participants, 94–97% of whom
experienced nasal congestion and/or obstruction [8].
These factors represent an immense challenge to GPs
when sorting potential cancer patients from the general
patient population.
The European Head and Neck Society launched the
Make Sense Campaign (MSC) in 2013 in order to inform
the general public and PHC personnel about HNC [9].
The MSC campaign website provides information about
risk factors and symptoms associated with HNC [9], while
introducing a “1-for-3” rule regarding symptoms and their
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persistence. Symptoms include: 1. a sore tongue, non-
healing mouth ulcers and/or red or white patches in the
mouth; 2. pain in the throat; 3. persistent hoarseness; 4.
painful and/or difficulty swallowing; 5. a lump in the
neck; and 6.a blocked nose on one side and/or bloody
discharge from the nose. The 1-for-3 rule states that, if a
patient experiences one or more of the six most common
HNC-related symptoms for more than three weeks, the
GP should refer the patient to a head and neck specialist.
The background population of patients who contact a
GP with a symptom potentially caused by HNC and
among whom a GP needs to identify suspected HNC
patients for further referral remains largely unexamined.
Here, we aimed to study this background population in
order to investigate the challenges encountered by a GP
related to detecting HNC patients. We hypothesised that
due to the rarity of HNC, their diagnostics in PHC is diffi-
cult. We also aimed to provide a rough estimate for the
likelihood that a PHC patient of a certain age with a spe-
cific symptom has HNC.
Patients and methods
We retrospectively investigated the total number of
patients attending outpatient visits at all 28 PHC
centres in the City of Helsinki, with a population of
635,181 in 2016, excluding emergencies. Data were col-
lected from the centralised electronic database man-
aged by the Social Services and Health Care Division of
Helsinki, which records every visit to a nurse or a GP.
The database contains all patient information recorded
through the patient record system Pegasos, that was
used in all 28 PHC centres. From this database, it is
possible to retrieve anonymous data from patient
appointments that include the patients’ age, sex and
the ICD-10 diagnosis code used. In Finland, it is com-
pulsory for a GP to select at least one diagnosis using
the ICD-10 codes most accurately describing the reason
for each PHC visit. However, it is not possible to auto-
matically gather any information written in text form.
We selected 57 ICD-10 codes we identified as repre-
senting a sign or symptom potentially caused by HNC,
examining how often they were used in our patient
population (Table 1). Data were then grouped accord-
ing to patient sex and age. We were unable to gather
information on the duration of symptoms. We chose
2016 as the year for our analysis, since we had previ-
ously meticulously examined different delays experi-
enced by our new HNC patients during that year,
including patient-related delays and PHC delays [10].
In Helsinki, all HNC patients are referred to and
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Department of Otorhinolaryngology – Head and Neck
Surgery or in the Department of Oral and Maxillofacial
Surgery). The treatment modality for all HNC patients in
the Helsinki and the surrounding region (Uusimaa), is
assessed in multidisciplinary tumour board meetings,
which are held weekly. We investigated all 111 new
HNC patients diagnosed from the population of
Helsinki in 2016. This area covers about one-third of
the total referral population of our university hospital.
We manually collected data on patients’ health-seeking
behaviour, the number of visits to a doctor before the
referral, the place from which the referral was made to
specialist care (SC), the delay from the initial PHC visit
until the referral to SC and the ICD-10 code for the
appointment from hospital records. Additionally,
regarding patients who were referred from PHC
(n¼ 40), we collected their data from the patient record
system that was used in the PHC centres (Pegasos).
Patient-related variables included age and sex.
The Research Ethics Board at the Hospital District of
Helsinki and Uusimaa approved the study design
(record number: 398/13/03/02/15) and an institutional
permit was granted. The Helsinki Social and Health
Care Services also approved the study protocol.
Results
Outpatient visits to primary health care
A total of 242,211 patients visited a GP in PHC in the
City of Helsinki in 2016, resulting in a total of 499,542
outpatient visits. Among these patients, 55.0% were
over 40 years old and 60.2% were female. In
December 2016, 380 GPs were concurrently working
at PHC centres in the City of Helsinki.
The total number of patients who visited a GP and
had a symptom potentially caused by HNC reached
11,896 (Figure 1). Among these patients, 61.4% were
female, 38.6% were male and 50.1% were over
40 years old. Table 1 summarises the distribution of
symptoms, ICD-10 codes and the corresponding num-
ber of patients for each category. The symptoms men-
tioned in MSC do not include difficulties breathing
and/or haemoptysis. The total number of patients who
visited a GP presenting with a symptom mentioned in
the MSC reached 8882 (61.3% female, 38.7% male), of
whom 42.6% were over 40 years old.
Head and neck cancer patients in the city
of Helsinki
In 2016, altogether 111 new HNCs were diagnosed
among residents of the City of Helsinki. Public PHC
centres referred 40 (36.0%) of them to SC (Figure 2). The
remaining patients were referred from the private sector
(n¼ 23; 20.7%), a public dentist (n¼ 20; 18.0%), other
hospital specialties (n¼ 12; 10.8%), a private dentist
(n¼ 11; 9.9%), occupational health care (n¼ 3; 2.7%) or
a hospital emergency unit (n¼ 1; 0.9%). One patient vis-
ited a public PHC centre in a neighbouring city.
A total of 40 new HNC patients were referred from a
public PHC centre to SC. Among these patients, 27
(67.5%) were male and 13 (32.5%) were female with a
mean age of 64 (range, 45–80 years). The most common
cancer sites among these patients were the oropharynx
(n¼ 15; 37.5%), oral cavity (n¼ 7; 17.5%), hypopharynx
(n¼ 6; 15%), nose and nasal cavity (n¼ 5; 12.5%), larynx
(n¼ 4; 10%), unknown primary (n¼ 2; 5%) and major
salivary glands (n¼ 1; 2.5%). All cancer sites according
to the place of referral appear in Table 2.
The most common symptom among the 40
patients referred from PHC (according to the ICD-10
diagnosis code used at the visit) was a lump in the
head and neck site (n¼ 10; 25%). Other symptoms
listed in order of frequency included: non-healing
mouth ulcers and/or red or white patches in the
mouth (n¼ 5; 12.5%); pain in the throat (n¼ 4; 10%);
painful and/or difficulty swallowing (n¼ 4; 10%);
blocked nose and/or bloody discharge from the nose
(n¼ 4; 10%); difficulties breathing and/or haemoptysis
(n¼ 4; 10%); and hoarseness (n¼ 2; 5%). Three
patients (7.5%) did not have any diagnosis code regis-
tered at their initial visit to PHC and 4 (10%) patients
had an ICD-10 diagnosis code that was not relevant or
was too general compared to their symptoms.
Half (n¼ 20; 50%) of the patients were referred to
SC during the initial visit to the PHC centre, 17
patients at the second visit and 3 patients during the
third visit. Two thirds of these additional visits (65%)
were related to an ultrasound and fine-needle sample,
while the remaining were clinical follow-up or other
visits. Only one patient who initially visited a public
PHC centre subsequently sought medical advice from
the private sector.
The median doctor-related PHC delay (from the ini-
tial visit at PHC to the referral to SC) was 5days (mean,
19days; range, 0–248days). More than half (57.5%) of
the patients were referred to SC within a week, 72.5%
within 2 weeks and 87.5% within 1 month. Only three
patients had a PHC delay of more than 2 months.
Discussion
In the present patient population consisting of
patients residing in the Helsinki area, a new HNC was
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detected roughly once in every 12,500 visits or in
every 6000 patients seen in PHC. Yet, the median doc-
tor-related PHC delay was no more than 5 days, and
half of the patients were referred to SC during the ini-
tial visit. The number of patients who presented with
a similar symptom potentially caused by HNC remains
largely unexamined. In our study, we collected data
from all patients who visited a PHC centre in the City
of Helsinki in 2016, amounting to a total of 242,211
patients. Among these patients, we identified 40 new
HNC cases. To our knowledge, this is the only study
that has thoroughly investigated the background
population of patients among whom a GP needed to
identify potential HNC patients for further referral.
In Finland, the management of all HNC patients is
regulated by governmental authorities, organized by
Figure 1. The total number of patients that visited PHC centres in the City of Helsinki in 2016 out of which 40 new HNCs were
diagnosed at the PHC centres.
4 M. NIEMINEN ET AL.
the public health care system and centralized at five
university hospitals. Patients can either seek medical
care through public PHC centres or private sector.
Additionally, all employers must provide occupational
health care services to their employees which are
organized either through public or private sector.
Public health care is almost entirely funded through
tax collection by the municipality that the patient
belongs to. Total payment limit for any health service
is 683 euros during a calendar year, after which all
care is entirely free for the patient. Private health
insurances are not widely used because of good avail-
ability and low cost of public PHC and occupational
health care. All sectors can similarly refer patients to
public SC unit for further investigation and treatment
of potential HNC.
In Finland, all head and neck malignancies are dis-
cussed at weekly multidisciplinary tumour board meet-
ings held at the five university hospitals. Private
treatment in the field of HNC does not exist; even the
most minor malignancies are referred to the public
SC unit.
If we assume that the patient population was dis-
tributed evenly across all 380 GPs working in PHC
centres, each GP would have had 1315 appointments
with 637 patients each year. Based on our series, with
this patient volume in an unselected patient material,
a single GP would diagnose an average of 3.2 HNCs
during a 30-year career. Compared to the extremely
low number of new HNC patients identified by a GP
and the vast number of other patients a single GP
sees each year, the median doctor-related PHC delay
of 5 days seems extremely low. Most notably in this
study setting, we were only able to study the doctor-
related delay from the initial PHC visit until the referral
to SC. Any system-related delay between the first con-
tact with PHC and the initial visit remains unknown.
The median of 1.5 visits before the referral to SC is
similar to two other studies regarding HNC and oral
cancer [11,12], but less than that reported in a system-
atic review examining oral cancer referrals [13]. Most
subsequent physician visits entailed ultrasound imag-
ing and fine-needle aspiration samples or to control
symptoms. Only a single HNC patient referred from
Figure 2. Places of referral of all new HNC cancer patients (n¼ 111) in the City of Helsinki in 2016.
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the private sector had previously visited a PHC centre
for the same symptom. Thus, in general, PHC appears
to effectively detect and refer potential HNC patients
to SC.
In our patient population, the annual number of
newly diagnosed HNC cases was 111, which is in line
with the annual number reported by the Finnish
Cancer Registry [14]. However, it is important to notice
that oral cancer was underrepresented in the cohort
consisting only patients referred from PHC centres.
Most of the oral cancers were referred to SC by
a dentist.
Regarding the division of labour in HNC between
medical doctors and dentists, the majority of HNC
patients were referred to SC by a medical doctor
(72%), which agrees with a study by Ligier et al. [15].
Around one third (n¼ 40) of the HNC patients were
referred from PHC. Oral cancers were underrepre-
sented in this patient group, since the majority of
these patients (64%) were referred from a public or
private dentist. In a systematic review consisting of 16
studies examining the referral of oral cancer patients
in PHC, fewer patients (44%) were referred by dentists
[13]. This difference might stem from national differen-
ces in medical practices and the availability of differ-
ent medical resources.
According to our evaluation, a new HNC was
detected in 1 of every 6000 patients or 12,500 visits to
PHC centres, whereby 5% of patients had HNC-related
symptoms. This proportion is significantly higher than
in another study by Alho et al., which investigated the
incidence of HNC in Northern Finland [11]. In their
study, anew HNC case was detected once in every
63,000 visits and 11% of patients who visited PHC had
HNC-related symptoms. However, major differences
differentiate the methods we used and those in their
study. Specifically, Alho et al. randomly selected 24 dif-
ferent PHC centres in Finland and collected data on
GP appointments for a four-week period, comparing
data on HNC patients diagnosed in Northern Finland
from1986 through 1996. We, on the other hand, col-
lected data from all PHC centres in the City of Helsinki
for a one-year period, and all of our HNC patients
came from the same area during the same time
period. These differences might explain the vary-
ing results.
According to our analysis, stratification according to
certain clinical characteristics results in a higher HNC
detection ratio. If patients younger than 40 years old
are ruled out, the ratio rises to 1:3300. The majority of
HNC patients were male (67.5%), indicating that the
likelihood of a 40-year-old man visiting a GP in PHC
would have a HNC stood at 1:2000. Luckily, patients
often present with various symptoms, which point
clinicians towards suspicion of a possible malignant
aetiology. Among all patients who presented with a
symptom possibly caused by HNC (Table 1), the ratio
between HNC and non-HNC patients was 1:360.
Taking into account only patients older than 40 years,
the ratio increases to 1:180. Similarly, taking into
account only 40-year-old males increases the ratio to
1:90. Among 40 year-old patients who reported one
of the six symptoms mentioned in the MSC, the ratio
of HNC to non-HNC patients was 1:107, while for 40-
year-old males with MSC symptoms, the ratio
increased to 1:63. Most notably in our study setting,
we were unable to gather information on symptom
duration. Thus, in this series, we were unable to evalu-
ate the effectiveness of the 3-week rule outlined in
the MSC.
In addition, certain cancer risk groups emerged.
HNC was particularly prevalent among males
60 years old who presented with one of the six
symptoms mentioned in the MSC. The likelihood of
cancer among this patient group varied between 0.5
and 3%, whereby ICD-10 codes associated with a
lump in the head and neck region represented the
most malicious symptom (Table 1). A cancer preva-
lence of 3% is strikingly high considering that HNC
risk factors such as tobacco smoking or heavy alcohol
use were not available. In a study of over 40-year-old
tobacco users (n¼ 4611), the prevalence of HNC
reached nearly 3% [16]. Given these findings, it is par-
ticularly important to consider HNC as a possible
cause for these symptoms if the symptoms are unex-
plained by an acute respiratory tract infection or other
distinct aetiology. This is particularly important if the
patient has a history of tobacco use and/or heavy
alcohol consumption and symptoms persisted for at
least three weeks. Moreover, this also suggests
that the MSC guidelines for patients and GPs are
Table 2. Number of HNC patients diagnosed in the Helsinki









Oral cavity 45 7 3 29 6
Oropharynx 31 15 10 2 4
Larynx 10 4 3 0 3
Hypopharynx 9 6 2 0 1
Nose and nasal cavities 8 5 2 0 1
Major salivary glands 5 1 3 0 1
Unknown primary 3 2 0 0 1
Total 111 40 23 31 17
aPrimary health care.
bMedical doctor.
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well-founded. Furthermore, the ratio might be even
higher if we had ICD codes specific to a neck mass.
Our data do not include the number of patients with
a probable HNC-related symptom any individual SC
specialist encountered; thus, the ratio in a selected
series at specialist outpatient clinics is likely higher. A
British study on a 2-week wait fasttrack referral system
implemented to reduce delays in patients with sus-
pected HNC found that 9.5% of patients referred
through the system had HNC [17].
One limitation of this study lies in the likely hetero-
geneity in the use of ICD-10 codes. Because determin-
ing the ICD-10 diagnosis code relies on a subjective
decision-making process from the treating physician,
the comparability of diagnoses remains limited. In
17.5% of our cases, the ICD-10 diagnosis code was not
used at all or was non-descriptive. This generates a
bias when assessing the relative cancer risks among
different patient groups. Importantly, the number of
doctor visits with a certain symptom-related ICD-10
diagnosis code does not reflect the prevalence of spe-
cific symptoms in the general population. That is, a
distinctive difference exists between a patient with a
symptom and a patient seeking medical advice
because of a symptom, which should alarm GPs, par-
ticularly if the symptom is potentially cancer related
and the patient has risk factors for a malignancy.
Furthermore, it is important to notice that usually only
a single ICD-10 code is used per visit; if patient visits
PHC with multiple symptoms, only the primary symp-
tom is recorded. Therefore, calculations which are too
precise or far-fetched conclusions should not be
made. Another apparent limitation is that the codes
include a large variety of different and often benign
conditions, particularly in the most commonly used
codes, such as difficulties breathing, pain in the throat
or painful swallowing and a blocked nose. These ICD-
10 codes can be used to describe anything from car-
diac arrest to a viral upper respiratory tract infection.
In addition, further limitations include the lack of data
on tobacco use and alcohol consumption. Despite
these obvious limitations related to the use of ICD-10
codes, they are currently the only practical way to
study symptom epidemiology in a large population
series before the emergence of structured patient
record systems.
To conclude, we identified one HNC patient for
every 6000 patients visiting PHC. If patients’ symp-
toms, age and sex were taken into account, this ratio
climbed to as high as 1:33 (60-year-old male with a
lump in the head and neck region). Despite the chal-
lenges in identifying HNC patients from the normal
patient flow, the median PHC delay was only 5 days
and delays of over a month occurred only in 12.5% of
all cases.
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